Note 15 - Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Notes to Financial Statements | |
| Subsequent Events [Text Block] |
Note 15. Subsequent Events
The Company has evaluated subsequent events through the date of the filing of this Quarterly Report and report the following.
Stock Issuances
Subsequent to June 30, 2026, we have sold 3,500,000 shares of our common stock to Clearthink (see Note 3) and received $376,000 in gross proceeds.
Clyra Medical Financing Activities
Subsequent to June 30, 2026, Clyra issued guaranteed promissory notes in the aggregate amount of $325,000 to five accredited investors. The notes bear interest at the rate of 15% per annum, mature July 31, 2029, and are guaranteed by BioLargo Inc. Each investor received a warrant to purchase an aggregate of number of Clyra common shares equal to the face amount of the note divided by 7.5, divided by two, at an exercise price of $7.50 per share, expiring July 31, 2031. Warrants to purchase an aggregate 21,666 shares of Clyra common stock were issued to the investors. |